Your Methylation System Has a Genetic Blueprint. Here's What It Reveals.

MTHFR encodes the enzyme that converts folic acid and B12 into their active, methylated forms. This is the first critical step in the methylation cycle, the biochemical pathway that powers energy production, detoxification, neurotransmitter synthesis, and gene expression. When MTHFR works normally, this conversion happens efficiently and your cells get the energy cofactors they need.

Here’s the problem: the MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces this enzyme’s efficiency by 40 to 70 percent. You can eat a perfect diet rich in folate and B12 and still be functionally depleted at the cellular level. Your cells simply cannot convert dietary folate into the methylated form they require. Standard B12 and folate blood tests appear normal because they measure total circulating levels, not cellular availability.

This manifests as persistent fatigue despite adequate sleep, brain fog that doesn’t improve with caffeine, depression or anxiety that seems disproportionate to life circumstances, and difficulty recovering from physical or mental stress. Your body is trying to run on partially converted fuel.

VDR is not the vitamin D itself, it’s the receptor that sits on your cell membrane and accepts vitamin D once it arrives. Think of it as the lock, and vitamin D as the key. Even if you have plenty of keys circulating in your blood, a defective lock means they can’t enter the cell. VDR variants determine how efficiently this handoff happens.

The VDR BsmI, FokI, and TaqI variants are carried by roughly 30 to 50% of the population. Certain VDR variants reduce cellular vitamin D uptake by 30 to 50 percent, meaning you need higher vitamin D levels in your blood just to achieve adequate cellular saturation. Standard supplementation based on blood levels leaves your cells chronically under-supported. Additionally, vitamin D controls mitochondrial biogenesis, the production of new energy-generating structures in your cells. A VDR variant that reduces uptake also reduces energy output at the mitochondrial level.

You experience persistent fatigue that doesn’t respond to vitamin D supplementation, seasonal mood changes even in sunny seasons, delayed wound healing, weak immune response, and muscle weakness despite adequate activity. Your cells simply cannot absorb the vitamin D your bloodwork says you have.

Vitamin D doesn’t travel through your bloodstream freely. It binds to a carrier protein called the vitamin D binding protein, encoded by the GC gene. Different GC haplotypes (1s, 1f, and 2) bind vitamin D with different affinities. This matters because vitamin D must be released from the carrier protein to enter your cells. If your GC variant binds vitamin D too tightly, more stays bound and less remains bioavailable, even if your total vitamin D level appears adequate.

GC variants are common across all populations. Certain GC haplotypes leave significantly less free, bioavailable vitamin D circulating in your tissues despite adequate supplementation. Your liver and kidneys can produce sufficient total vitamin D, but if your GC variant is a tight binder, your tissues get less of what they need. This compounds the problem if you also carry a VDR variant that reduces cellular uptake.

You notice that vitamin D supplementation boosts your blood levels but doesn’t actually improve your symptoms. Seasonal fatigue persists despite adequate supplementation. Immune function remains weak. Calcium absorption doesn’t improve even with supplementation. The vitamin D is there, but it’s bound and unavailable.

Your body cannot produce vitamin A; you must obtain it from food. You can eat it directly as preformed vitamin A from animal products, or you can eat beta-carotene from plants and let your BCMO1 enzyme convert it into retinol. BCMO1 is the gateway enzyme for plant-based vitamin A. When this gene works efficiently, you can get adequate vitamin A from a plant-forward diet.

The BCMO1 R267S and A379V variants are carried by roughly 45% of the population. These variants reduce beta-carotene conversion efficiency by 50 to 80 percent, meaning your body cannot extract adequate vitamin A from plant sources alone. You can eat plenty of carrots, sweet potatoes, and leafy greens and still develop functional vitamin A deficiency. This is especially problematic if you follow a vegetarian or vegan diet.

You experience poor night vision, dry skin and mucous membranes, difficulty fighting infections, impaired wound healing, and reproductive issues. Your eyes struggle to adapt to dim light. Your skin feels perpetually dry despite moisturizing. Vitamin A is critical for retinal function, immune response, and skin barrier integrity, and if your BCMO1 conversion is impaired, plants alone cannot provide enough.

B6 plays a role in over 100 enzymatic reactions in your body, but only the active form, pyridoxal-5-phosphate (PLP), actually does the work. Your cells must convert dietary B6 into PLP to use it. The NBPF3 gene controls this activation step. When this gene functions normally, the conversion is efficient and you maintain adequate PLP levels even on modest B6 intake.

The NBPF3 rs4654748 variant is carried by roughly 30 to 40% of the population. This variant is associated with chronically lower pyridoxal-5-phosphate levels in your blood, even when total B6 appears adequate. Standard B6 blood tests often measure total B6, not active PLP, so deficiency can be completely hidden. Yet your cells are operating with insufficient active B6, impacting energy metabolism, neurotransmitter synthesis, and immune function.

You experience unusual fatigue despite normal energy levels on paper, impaired mood regulation and anxiety, poor muscle recovery after exercise, weakened immune response, and worsening of premenstrual symptoms if female. B6 is essential for serotonin and dopamine synthesis; insufficient PLP leaves you neurologically under-supported. Your muscles cannot recover efficiently because B6 is needed for protein metabolism.

COMT breaks down dopamine, norepinephrine, and epinephrine after these neurotransmitters have done their job. This cleanup is essential for healthy stress response, focus, mood, and sleep. If COMT works efficiently, your nervous system returns to baseline after stress. If COMT is slow, these stimulating neurotransmitters linger, keeping your nervous system activated even when there’s no threat.

The COMT Val158Met variant determines whether you are a fast or slow clearance type. Roughly 25% of people are homozygous slow (Met/Met). Slow COMT means dopamine, norepinephrine, and epinephrine clear more slowly from your synapses, leaving your nervous system chronically overstimulated. This manifests as difficulty falling asleep despite being exhausted, racing thoughts at night, anxiety that feels disproportionate, tension headaches, and inability to tolerate caffeine or high-intensity exercise. Your stress response doesn’t turn off.

This becomes especially problematic when combined with MTHFR variants because MTHFR controls the production of these same neurotransmitters. If you have both slow COMT and an MTHFR variant, you’re both underproducing neurotransmitters and clearing them slowly, creating a pattern of depletion followed by overstimulation.